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Abstract
Introduction Finding new immunohistochemical markers that
are specific to hereditary breast cancer could help us to select
candidates for BRCA1/BRCA2 mutation testing and to
understand the biological pathways of tumour development.
Methods Using breast cancer tumour microarrays,
immunohistochemical expression of cytokeratin (CK)-5/6, CK-
14 and CK-17 was evaluated in breast tumours from BRCA1
families (n = 46), BRCA2 families (n = 40), non-BRCA1/
BRCA2 families (n = 358) and familial breast cancer patients
with one first-degree relative affected by breast or ovarian
cancer (n = 270), as well as from patients with sporadic breast
cancer (n = 364). Staining for CK-5/6, CK-14 and CK-17 was
compared between these groups and correlated with other
clinical and histological factors.
Results CK-5/6, CK-14 and CK-17 were detected mostly
among oestrogen receptor (ER)-negative, progesterone
receptor (PR)-negative and high-grade tumours. We found the
highest percentages of samples positive for these CKs among
ER-negative/HER2-negative tumours. In univariate analysis, CK-
14 was significantly associated with tumours from BRCA1
(39%; P < 0.0005), BRCA2 (27%; P = 0.011), and non-
BRCA1/BRCA2 (21%; P < 0.005) families, as compared with
sporadic tumours (10%). However, in multivariate analysis, CKs
were not found to be independently associated with BRCA1 or
BRCA2 mutation status, and the most effective predictors of
BRCA1 mutations were age at onset, HER2 status, and either
ER or PR status.
Conclusion Although our study confirms that basal CKs can
help to identify BRCA1 mutation carriers, this effect was weaker
than previously suggested and CKs did not independently
predict BRCA1 mutation either from sporadic or familial breast
cancer cases. The most effective, independent predictors of
BRCA1 mutations were age at onset, HER2 status, and either
ER or PR status, as compared with sporadic or non-BRCA1/
BRCA2 cancers.
Introduction
Human breast cancers form a heterogeneous group of can-
cers. There are many subclassifications, and attempts have
been made to identify differences between and characterize
such subgroups. Earlier immunohistochemical studies, and
recently gene expression studies as well, have been con-
ducted to classify tumours [1]. One of the subgroups pro-
posed is the so-called basal-like group of tumours, which are
associated with breast cancers that express neither oestrogen
receptor (ER) nor human epidermal growth factor receptor
(HER)2, but express frequently 'basal' cytokeratins (CKs) such
as CK-5/6, CK-14 and CK-17. These CKs are intermediate fil-
aments that are found in the cells of the basal layer of normal
breast ducts. Therefore, the term 'basal' is generally used,
although the origin of breast tumour cells expressing these
CKs is unknown. Moreover, the definition of basal phenotypePage 1 of 8
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classified as basal-like by microaray analysis express basal
CKs [2]. In general, these tumours are associated with high
grade and stage [3], but conflicting findings have been
reported regarding the independent prognostic significance of
the basal phenotype [4]. Although basal CK expression may
predict early relapse among nonselected tumours, the clinical
outcome of basal tumours has been found to be similar to that
of nonbasal ER-negative tumours [5].
The general features of basal phenotype tumours are the same
as those of tumours in BRCA1 mutation carriers [1]. In partic-
ular, expression of CK-5/6 [6,7] and CK-5/14 [8] has been
associated with BRCA1 tumours. Moreover, Lakhani and col-
leagues [9] tested five basal markers (CK-14, CK-5/6, CK-17,
epidermal growth factor and osteonectin), all of which were
significantly associated with BRCA1 tumours as compared
with unselected breast tumours.
In addition to the CKs, it has been clear for some time that
BRCA1-associated tumours have distinct pathological fea-
tures when compared with sporadic cancers. BRCA1
tumours have higher tumour grade, less ER and progesterone
receptor (PR) expression, less HER2 expression and over-
expression of p53, and a higher proportion of medullary than
sporadic cancers [10]. Furthermore, they exhibit high Ki-67-
index and over-express proteins such as cyclin-E, cyclin-A and
cyclin-B1 [10]. The pathological phenotype of BRCA2-associ-
ated tumours is inconsistent, and in many cases no significant
differences have been found between BRCA2-associated and
sporadic cancers [11-13]. However, some studies have found
BRCA2-associated tumours to be negative for HER2 and to
over-express CHEK2 (checkpoint kinase 2) and RAD51
(homolog of Saccharomyces cerevisiae Rad51) [10]. The
basal CK frequencies have been found to be similar in this
group of tumours and sporadic ones [9].
There is much need for markers that could be used to distin-
guish patients and families who are likely to carry a BRCA1/
BRCA2 germline mutation from mutation-negative families
and from breast cancer patients in general. Such markers
could facilitate targeting of expensive and time-consuming
genetic testing to individuals who are most likely to carry those
mutations. It is also necessary to learn more about the biolog-
ical characteristics of these tumours in order to foster develop-
ment of less radical prevention strategies than risk-reducing
surgery and to identify possible targets for drug development.
It has been suggested that CK-5/6, CK-14, P-cadherin and
epidermal growth factor receptor may have utility as a first-line
immunohistochemical test for the presence of germline
BRCA1 mutation [14]. In this study, we evaluated expression
of basal CKs among tumours from BRCA1, BRCA2 and non-
BRCA1/BRCA2 families (families with several breast cancer
patients without BRCA1 or BRCA2 mutations), and sporadic
breast cancer patients. It is important to compare tumours of
mutation carriers with tumours from families including several
cancer cases, and not just to compared them with sporadic
tumours, because this is the situation usually encountered in
the clinical setting of genetic counselling.
Materials and methods
Breast cancer patients and tumours
A series of 884 consecutive, newly diagnosed breast cancer
patients was recruited from the Department of Oncology (Hel-
sinki University Central Hospital) during the period from 1997
to 1998 and during the year 2000, as described in detail by
Syrjäkoski and coworkers [15] and Kilpivaara and colleagues
[16]. Familial breast cancer patients (n = 546) were recruited
from the Departments of Oncology and Clinical Genetics, as
described by Eerola and coworkers [17]. This series includes
breast cancer families with at least three first-degree or sec-
ond-degree relatives with breast or ovarian cancer, as well as
patients with one first-degree relative affected by breast or
ovarian cancer, with no restriction on age. All of the breast can-
cer families and unselected patients were tested for BRCA1
and BRCA2 mutations by mutation analysis of the entire cod-
ing sequences and exon/intron boundaries of the genes using
protein truncation test and denaturing gradient gel electro-
phoresis, or as previously described [18-20], except for 158
patients from families with two affected members, in whom
BRCA1 and BRCA2 mutation status was not determined.
We collected all available paraffin blocks containing enough
tumour tissue from primary breast cancers of unselected and
familial breast cancer patients, and the most representative
area of the tumour was punched to produce a breast cancer
tissue microarray (TMA), including two to four cores (diameter
0.6 mm) from each original block, as partially described previ-
ously [21]. Altogether, the TMAs included 1,335 invasive
breast cancer tumours; 921 of these were from familial
patients (577 from families with three or more first-degree or
second-degree relatives with breast or ovarian cancer, includ-
ing the proband, and 344 from families with two affected first-
degree relatives) and 414 from sporadic patients (patients
without the above-defined family history of breast or ovarian
cancer). Fifty-two of the tumours from familial patients were
from patients of families positive for BRCA1 mutation and 56
tumours were from patients of families positive for BRCA2
mutation.
In this study we excluded lobular carcinomas as ambiguous,
as well as tumours from noncarriers in the BRCA1/BRCA2
families and tumour from patients for whom no representative
tumour tissue was available on the TMA arrays. Finally, the
staining findings was obtained for a total of 1,078 tumours,
which included 622 cancers from the unselected breast can-
cer patient series. Combined with the family material, CK
expression was evaluated in the following: 46 cancers from
BRCA1 families; 40 cancers from BRCA2 families; 358 can-
cers from non-BRCA1/2 families; 270 cancers from patientsPage 2 of 8
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breast or ovarian cancer; and 364 cancers from patients with
sporadic breast cancer (patients with no family history of
breast cancer).
We studied haematoxylin and eosin stained sections of the
original blocks for histological diagnosis and grading (by the
same pathologist [PH]) Grading was performed using the
Scarff-Bloom-Richardson method, as modified by Elston and
Ellis [22]. All of the TMA slides were stained with antibodies to
CK-5/6, CK-14 and CK-17. Briefly, 5 μm sections were cut
from paraffin-embedded blocks, deparafinated in xylene and
dehydrated in a series of graded alcohols. Sections that were
immnunostained with antibodies against CK-5/6 (dilution
1:25; Dako, Glostrup, Denmark) and CK-14 (dilution 1:20;
Novocastra, Newcastle upon Tyne, UK) were first pretreated in
a microwave oven in Tris-EDTA (pH 9.0), incubated with the
primary antibodies for 30 minutes and visualized using the
Envision detection system (Dako) and LabVision autostainer
(Thermo Fisher Scientific Inc., Fremont, CA, USA). Sections
that were immunostained with antibodies against CK-17 (dilu-
tion 1:20; Vector Laboratories, Burlingame, CA, USA) were
first pretreated in a microwave oven in 10 mmol/l citric acid
(pH 6.0), incubated with primary antibodies for 30 minutes
and visualized using (Renaissance) TSA-Biotin system NEL
700 kit (PerkinElmer, Massachusetts, USA). Specimens were
considered negative if immunopositivity was found in 0% to
10% and positive if 11% to 100% of the cancer cells exhibited
immunopositivity. A cut-off value of >10% results in clearly
positive staining.
All the TMA slides were stained using routine methodology
with p53 antibodies (1:300; Dako, Copenhagen, Denmark;
described previously by Eerola and coworkers [21]). Samples
were considered positive when 20% of the cancer cells
stained positive. Amplification of the HER2 oncogene was
determined by chromogenic in situ hybridization (as described
by Tanner and coworkers [23]); none to five replications was
considered negative, and more than six replications was con-
sidered positive. Information on ER and PR status was
acquired from pathology reports. The staining methodology
and evaluation of the results are applied routinely in breast
cancer diagnostics and are previously described by Eerola
and coworkers [21]. Samples were considered positive when
10% of the cancer cells stained positive. The information on
stage was acquired from patient records.
Statistical analysis
Statistical analysis was conducted using SPSS for Windows
(SPSS Inc., Chigaco, IL, USA). We tested the differences in
dichotomous variables by χ2 test or Fisher's exact test, and
multivariate analysis was conducted using logistic regression
(backward conditional, P for stepwise removal 0.05). All P val-
ues are two sided.
Ethics
The study was performed with informed consent from the
patients as well as with approval from the Ethics Committee
(E8) of the Helsinki University Central Hospital and from the
Ministry of Social Affairs and Health in Finland.
Results
Tumours expressing basal CKs (CK-5/6, CK-14 and CK-17)
were more likely to be ER negative and PR negative, and to
occur in younger breast cancer patients. CK-5/6 expression
was also significantly associated with high grade and p53
positivity, and expression of CK-5/6 and CK-14 with HER2
negativity. CK14 was significantly associated with BRCA1
mutation but also with BRCA2 and non-BRCA1/BRCA2
groups of cancers, as compared with sporadic breast cancers
(Table 1). We found all three CK markers to be highly signifi-
cantly associated with the subgroup of tumours negative for
both ER and HER2. Within this subgroup of cancers, CK-5/6
was positive in 33% of 167 cancers (P < 0.0005), CK-14 in
35% of 161 cancers (P < 0.0005), and CK-17 in 10% of 158
cancers (P = 0.001), as compared with 9%, 11% and 4%,
respectively, among the tumours in which one or both of the
markers (ER of HER2) was positive.
BRCA1 associated cancers were more often high grade, ER
negative, PR negative, p53 positive and HER2 negative, as
well as CK 14 positive, as compared with all other groups
(Table 2). CK-5/6 frequency was also higher but not signifi-
cantly so if compared with non-BRCA1/BRCA2 or sporadic
cancers. However, in multivariate analysis, including all factors
from Table 2, neither CK-5/6 nor CK-14 were independent
predictors of BRCA1 mutations. After stepwise removal of
markers that were not significant at the 5% level, independent
predictors were found to be age at onset, HER2 negativity and
ER and/or PR status, depending on the analysis. In the analy-
sis comparing BRCA1 tumours with sporadic tumours, the
factors in the final model were ER (for negative status: odds
ratio [OR] = 11.2, 95% confidence interval [CI] = 4.3 to 29.2),
HER2 (for negative status: OR = 4607.4, 95% CI = 0 to 3.8
× 1021) and age at onset (for age <50 years: OR = 4.3, 95%
CI = 1.6 to 11.2). Compared with non-BRCA1/BRCA2 fami-
lies the final model included PR (for negative status: OR =
10.0, 95% CI = 3.5 to 28.6), HER2 (for negative status: OR
= 4309.7, 95% CI = 0 to 3.3 × 1024) and age at onset (for age
<50 years: OR = 5.0, 95% CI = 1.9 to 13.1).
BRCA2-associated tumours were also significantly more often
negative for ER, PR and HER2, and detected at earlier age
than sporadic tumours or non-BRCA1/BRCA2 tumours. CK-
14 was expressed more frequently than among sporadic can-
cers. However, in multivariate analysis, including all significant
variables from univariate analysis, the only independent predic-
tors of BRCA2 mutation were the age at onset under 50 years
(OR = 3.7, 95% CI = 1.5 to 8.7), PR negativity (OR = 2.9,
95% CI = 1.2 to 6.9) and HER2 negativity (OR = 3705.2,Page 3 of 8
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Association of CK-5/6, CK-14 and CK-17 with clinicopathological features
All % CK-5/6 CK-14 CK-17
Positive/alla % P Positive/alla % P Positive/alla % P
All 1078 100 129/982 13.1 151/955 15.8 41/931 4.4
Oestrogen receptor
Negative 266 26.0 67/241 27.8 <0.0005 63/236 26.7 <0.0005 20/236 8.5 0.001
Positive 757 74.0 56/692 8.1 78/671 11.6 21/650 3.2
Progesterone receptor
Negative 388 38.0 74/353 21.0 <0.0005 76/348 21.8 <0.0005 26/346 7.5 <0.001
Positive 633 62.0 49/578 8.5 65/557 11.7 15/538 2.8
Grade
I 231 21.6 17/194 8.8 <0.0005 32/193 16.6 0.097 3/185 1.6 0.021
II 453 42.5 43/420 10.2 52/403 12.9 15/391 3.8
III 383 35.9 69/359 19.2 65/350 18.6 23/347 6.6
T
1 649 61.3 69/580 11.9 0.159 89/556 16.0 0.790 27/549 4.9 0.434
2 to 4 409 38.7 58/386 15.0 59/384 15.4 14/366 3.8
N
0 596 56.6 72/538 13.4 0.607 85/524 16.2 0.477 23/506 4.5 0.659
1 457 43.4 52/424 12.3 60/413 14.5 16/405 4.0
M
0 997 96.5 122/910 13.4 0.882 144/885 16.3 0.269 39/861 4.5 0.706
1 36 3.5 4/32 12.5 3/33 9.1 1/32 3.1
p53
Negative 772 76.5 76/732 10.4 <0.0005 108/718 15.0 0.264 27/687 3.9 0.120
Positive 237 23.5 51/230 22.2 40/220 18.2 14/217 6.5
HER2
Negative 774 84.9 107/756 14.2 0.058 132/740 17.8 <0.0005 34/709 5.7 0.764
Positive 138 15.1 11/135 9.3 7/133 5.3 5/120 4.2
Age (years)
≥50 668 62.0 65/603 10.8 0.006 80/580 13.8 0.033 19/570 3.3 0.045
<50 410 38.0 64/379 16.9 71/375 18.9 22/361 6.1
BRCA1 46 4.3 6/34 17.6 0.250b 13/33 39.4 <0.0005b 1/43 2.3 0.866b
BRCA2 40 3.7 2/26 7.7 0.599b 7/26 26.9 0.011b 0/34 0 0.326b
Non-BRCA1/BRCA2 358 33.2 44/333 13.2 0.383b 67/324 20.7 <0.0005b 11/320 3.4 0.624b
Two affected 270 25.0 40/253 15.8 0.087b 30/244 12.3 0.469b 20/209 9.6 0.001b
Only sporadic 364 33.8 37/336 11.0 Ref. 34/328 10.4 Ref. 9/325 2.8 Ref.
a Positive staining/samples available. bCompared with 'only sporadic'. CK, cytokeratin; HER, human epidermal growth factor receptor.Page 4 of 8
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Association of clinicopathological features among tumours of BRCA1 families, BRCA2 families, non-BRCA1/BRCA2 families and 
two-affected families compared with tumours from patients with sporadic breast cancer
BRCA1 cases BRCA2 cases Non-BRCA1/BRCA2 Two affected Sporadic
n % P n % P n % P n % P n %
All 46 40 358 270 364
Oestrogen receptor
Negative 33 75.0 <0.0005 15 38.5 0.013 79 24.3 0.294 64 24.9 0.248 75 20.9
Positive 11 25.0 24 61.5 246 75.7 193 75.1 283 79.1
Progesterone receptor
Negative 37 84.1 <0.0005 21 53.8 0.014 115 35.6 0.657 93 36.3 0.548 122 34.0
Positive 7 15.9 18 46.2 208 64.4 163 63.7 237 66.0
Grade
I 1 2.2 <0.0005 8 20.0 0.933 82 23.5 0.717 59 21.9 0.974 81 22.3
II 11 24.4 17 42.5 154 44.1 117 43.3 154 42.4
III 33 73.3 15 37.5 113 32.4 94 34.8 128 35.3
T
1 21 46.7 0.079 18 54.5 0.516 229 65.6 0.144 162 60.4 0.976 219 60.3
2 to 4 24 53.3 15 45.5 120 34.4 106 39.6 144 39.7
N
0 32 71.1 0.026 15 44.1 0.289 214 61.1 0.043 142 53.8 0.965 193 53.6
1 13 28.9 19 55.9 136 38.9 122 46.2 167 46.4
M
0 41 93.2 0.570 28 90.3 0.245 338 98.8 0.005 255 96.6 0.386 335 95.2
1 3 6.8 3 9.7 4 1.2 9 3.4 17 4.8
p53
Negative 25 62.5 0.017 26 76.5 0.707 261 76.5 0.399 193 75.1 0.233 267 79.2
Positive 15 37.5 8 23.5 80 23.5 64 24.9 70 20.8
HER2
Negative 30 100 0.017 27 100 0.023 256 85.3 0.598 192 82.1 0.587 269 83.8
Positive 0 0 0 0 44 14.7 42 17.9 52 16.2
CK-5/6
Negative 28 82.4 0.250 24 92.3 0.599 289 86.8 0.383 213 84.2 0.087 299 89.0
Positive 6 17.6 2 7.7 44 13.2 40 15.8 37 11.0
CK-14
Negative 20 60.6 <0.0005 19 73.1 0.011 257 79.3 <0.0005 214 87.7 0.469 294 89.6
Positive 13 39.4 7 26.9 67 20.7 30 12.3 34 10.4
CK-17
Negative 42 97.7 0.866 34 100 0.326 309 96.6 0.624 189 90.4 0.001 316 97.2
Positive 1 2.3 0 0 11 3.4 20 9.6 9 2.8
Age (years)
≥50 16 34.8 <0.0005 22 55.0 0.004 215 60.1 0.035 97 35.9 0.356 246 67.6
<50 30 65.2 18 45.0 143 39.9 173 64.1 118 32.4
CK, cytokeratin; HER2, human epidermal growth factor receptor 2.Page 5 of 8
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tumours.
Tumours from familial non-BRCA1/BRCA2 patients were sim-
ilar to sporadic ones, although they were of lower stage and
CK-14 was expressed more often than among sporadic
tumours (Table 2). Age at onset was slightly younger than
among patients with sporadic breast cancer (median age at
onset: 54 and 57 years; P = 0.001). Tumours from families
with two affected members did not differ from sporadic
tumours.
Discussion
In this study expression of CK-5/6, CK-14 and CK-17 was
found to be strongly associated with the subgroup of tumours
negative for ER and HER2, as suggested previously for the
basal subgroup of breast tumours [3]. However, although our
study confirms that basal CKs, especially CK-14, can help to
identify BRCA1 mutation carriers, this effect was weaker than
in previous studies.
Because of differences in antibodies, staining and tissue
processing procedures in different studies, it is difficult to
compare findings between studies directly. For example, we
chose a cut-off point (>10%) for CKs that results in clearly
positive staining. Previously, rather different cut-off points had
been used, from any positivity to 20%. However, the frequen-
cies in the present study among unselected breast cancer
patients correlate with the previous literature, in which about
2% to 19% of unselected breast cancers were positive for
CK-5, CK-6 and CK-14 [7-9,24,25]. Moreover, the subgroups
in our study are comparable because the material was col-
lected uniformly from the same hospital, and microarray tissue
blocks enable staining of all samples at the same time and
under the same conditions. Highly significant correlations
between findings obtained using this kind of multicore system
and of whole sections of the original blocks have also been
demonstrated [26,27].
Similarly to previous studies, we found that expression of any
one or all of the markers CK-5/6, CK-14 and CK-17 correlates
with ER negativity [4,8,24], PR negativity [8], high grade
[4,8,24,25], early age at diagnosis [4,24,25] and p53 positiv-
ity [4]. Numerous studies have reported that basal CKs are
more frequently positive in BRCA1 tumours than in sporadic
breast cancers [6-9]. In our study as well, CK-14 was signifi-
cantly associated with BRCA1 carrier status, and CK-5/6 fre-
quency was also higher than among sporadic breast cancers
but the difference was not statistically significant. In the study
conducted Lakhani and coworkers [9], 57.6% of the BRCA1-
associated tumours stained positive for CK-5/6 and 60.6% for
CK-14. Corresponding figures in our study were 17.6% and
39.4%, although the percentages in control populations in
both studies were similar (Table 2).
In the study conducted by Foulkes and colleagues [6], CK-5/
6 was detected in 56% of the 72 ER/HER2-negative cancers,
and the frequency was even higher (88%) among the 17
BRCA1 mutation carriers with ER/HER2-negative cancers. In
our study CK-5/6 positivity was detected in a large proportion
(33%) of the 167 ER/HER2-negative cancers as well, but only
in 25% of the 20 ER/HER2-negative and BRCA1-related can-
cers. CK-14 was detected in 35% of 161 ER/HER2-negative
cancers and 37% of the ER/HER2-negative and BRCA1-pos-
itive group.
Few studies have used multivariate analysis to address the sig-
nificance of basal CKs in predicting BRCA1 mutations. In the
study conducted by Lakhani and colleagues [9], CK-14, CK-
5/6, CK-17, osteonectin, epidermal growth factor receptor,
ER and grade were included in a multiple regression model.
They found that independent markers for BRCA1 positivity
were ER, CK-5/6 and CK-14. In our multivariate analysis,
including all factors significant in univariate analysis, the stud-
ied basal CKs were not independent predictors of BRCA1
mutation status. However, in the multivariate analysis with only
basal CKs together with ER and grade, as in the study by
Lakhani and colleagues [9], the remaining significant factors
were CK-14 (OR = 3.3, 95% CI = 1.4 to 7.9) and ER (OR =
6.2, 95% CI = 2.7 to 14.2). Thus, the effect of CK-14 was sim-
ilar to that detected by Lakhani and colleagues. However, the
CK-5/6 result was different from their study, because it was
not significant in univariate or multivariate analysis. One factor
that may affect this is the strong association of CK-5/6 with
age at diagnosis, as shown in Table 1. The tumours included
in our study were unselected for age, and about 35% of the
BRCA1 tumours in our study were diagnosed at age 50 years
or older. We previously showed that tumours of BRCA1 and
BRCA2 carriers aged 50 years or older differ significantly from
those of younger patients [28]. However, CK-14 expression
correlates strongly with the HER2 status, as well as with ER
and PR status, and if we included all of these studied variables
in the logistic regression analysis, then the remaining inde-
pendent factors for BRCA1 mutation, in the final model, were
only age at onset, HER2 negativity and ER and/or PR status,
depending on the analysis. Age at onset, HER2 and PR were
not included in multivariate analysis conducted by Lakhani and
colleagues [9].
We also detected CK-14-positive staining among 27% of
BRCA2 associated tumours and 21% of the non-BRCA1/
BRCA2 associated tumours. These proportions are signifi-
cantly higher than the 10% among the sporadic tumours (P =
0.011 and P < 0.0005, respectively). This finding could be
influenced by chance in a low population frequency with mul-
tiple testing, or by the younger age in these subgroups com-
pared with the older patients with sporadic breast cancer,
because CK expression also correlates with tumours occur-
ring at earlier ages. In multivariate analysis, CKs were not inde-
pendently associated with BRCA2 mutation status. ToPage 6 of 8
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non-BRCA1/BRCA2 families, we conducted the same analy-
sis after excluding families with ovarian cancer cases, but this
did not alter the results. In the study conducted by Lakhani and
colleagues [9], none of the basal markers was significantly
associated with BRCA2 status. However, in their study as
well, the frequencies of CK-5/6 (15%) and CK-14 (24%) were
higher among BRCA2 cases than among controls (7% and
12%).
Conclusion
ER and PR strongly correlate with each other (Pearson's R =
0.657, P < 0.0005 in this study), and both of them were found
to be effective in predicting BRCA1 mutation. However,
although our study confirms that basal CKs can help to identify
BRCA1 mutation carriers, this effect was weaker than previ-
ously suggested and CKs did not independently predict
BRCA1 mutation either in sporadic or familial breast cancer
cases. One factor that may affect this is the strong association
of CK-5/6 with age at diagnosis, because the tumours
included in our study were unselected for age and about 35%
of the BRCA1 tumours in our study were diagnosed at age 50
years or older. In our material CKs also correlated strongly with
many other tumour characteristics, such as ER negativity, PR
negativity, high grade, p53 positivity, HER2 negativity and age
at onset. If we consider all factors analyzed, the most effective
independent predictors of BRCA1 mutations were age at
onset, HER2 status and either ER or PR status. The same fac-
tors appear also to predict BRCA2 mutations, although not as
strongly as BRCA1 mutations.
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